- AuthorisedTherapeutic use (Phase IV)
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
This study looks at how certain blood pressure and heart medications might help people with type 2 diabetes, who haven't had heart problems before, to avoid future heart issues. It focuses on a specific blood marker (NT-proBNP) to guide treatment.
For: Diabetes mellitus Type 2Spain · Austria - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
For: Immunoglobulin A NephropathyUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
This study is looking into a new medication called XXB750 for people with heart failure. It hopes to see how well it works, what dose is best, and if it's safe compared to a dummy treatment or existing medicines.
For: Heart FailureNetherlands · Italy · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
For: Focal segmental glomerulosclerosis (FSGS)Germany · Belgium · France